IRIDEX (NASDAQ:IRIX) Coverage Initiated at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX – Free Report) in a research report report published on Monday. The firm issued a hold rating on the medical equipment provider’s stock.

IRIDEX Stock Down 20.8 %

Shares of NASDAQ:IRIX opened at $0.80 on Monday. The company has a market capitalization of $13.31 million, a P/E ratio of -1.19 and a beta of 0.94. The stock’s fifty day simple moving average is $1.49 and its 200-day simple moving average is $1.64. IRIDEX has a 52-week low of $0.78 and a 52-week high of $3.65. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55.

About IRIDEX

(Get Free Report)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Further Reading